Literature DB >> 8533406

Drug-resistant Mycobacterium tuberculosis in California, 1991 to 1992.

D Koo1, S Royce, G W Rutherford.   

Abstract

To determine the proportion and distribution of drug-resistant Mycobacterium tuberculosis in California, we surveyed all California counties for drug-susceptibility test results for initial isolates from tuberculosis cases counted during the first quarters of 1991 and 1992. Overall, drug-susceptibility test results were not available for 17% of isolates. Among isolates with available test results, the proportion with resistance to isoniazid averaged 8.7%, and the proportion with resistance to at least 2 drugs, multidrug resistance, averaged 5.9% during these two quarters. The proportion of isolates with drug resistance did not change substantially during these time periods. The proportion with combined isoniazid and rifampin resistance remained stable at about 1.1%. Among persons whose isolates were tested for drug resistance, those with a known previous diagnosis of tuberculosis (relative risk [RR] = 2.6; 95% confidence interval [CI], 1.6 to 4.3; P < .01) and persons who were foreign born (RR = 1.7; 95% CI, 1.1 to 2.7; P = .014) were more likely to have isoniazid-resistant organisms. These statewide data suggest that the initial tuberculosis treatment regimen in California should include 4 antituberculosis drugs, as recommended by the American Thoracic Society and the Centers for Disease Control and Prevention for areas with a prevalence of isoniazid resistance of 4% or greater. The lack of test results for 1 in 6 patients with tuberculosis suggests the need for improved physician and laboratorian education to implement the recommendations that drug susceptibility be tested on all initial isolates.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8533406      PMCID: PMC1303167     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  8 in total

1.  A continuing survey of tuberculosis primary drug resistance in the United States: March 1975 to November 1977. A United States Public Health Service cooperative study.

Authors:  D E Kopanoff; J O Kilburn; J L Glassroth; D E Snider; L S Farer; R C Good
Journal:  Am Rev Respir Dis       Date:  1978-11

2.  Drug-resistant tuberculosis.

Authors:  D E Snider; G M Cauthen; L S Farer; G D Kelly; J O Kilburn; R C Good; S W Dooley
Journal:  Am Rev Respir Dis       Date:  1991-09

3.  An outbreak of tuberculosis caused by multiple-drug-resistant tubercle bacilli among patients with HIV infection.

Authors:  M A Fischl; R B Uttamchandani; G L Daikos; R B Poblete; J N Moreno; R R Reyes; A M Boota; L M Thompson; T J Cleary; S Lai
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

4.  The influence of epidemiologic factors on drug resistance rates in tuberculosis.

Authors:  P F Barnes
Journal:  Am Rev Respir Dis       Date:  1987-08

5.  Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis. A risk to patients and health care workers.

Authors:  M L Pearson; J A Jereb; T R Frieden; J T Crawford; B J Davis; S W Dooley; W R Jarvis
Journal:  Ann Intern Med       Date:  1992-08-01       Impact factor: 25.391

6.  Nationwide survey of drug-resistant tuberculosis in the United States.

Authors:  A B Bloch; G M Cauthen; I M Onorato; K G Dansbury; G D Kelly; C R Driver; D E Snider
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

7.  The emergence of drug-resistant tuberculosis in New York City.

Authors:  T R Frieden; T Sterling; A Pablos-Mendez; J O Kilburn; G M Cauthen; S W Dooley
Journal:  N Engl J Med       Date:  1993-02-25       Impact factor: 91.245

8.  The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis infections: a community-based study.

Authors:  L W Riley; E Arathoon; V D Loverde
Journal:  Am Rev Respir Dis       Date:  1989-05
  8 in total
  1 in total

Review 1.  Tuberculosis and HIV infection: a review.

Authors:  D Schürmann; S D Nightingale; F Bergmann; B Ruf
Journal:  Infection       Date:  1997 Sep-Oct       Impact factor: 7.455

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.